, SCr 2.0 mg/ dL, BUN 21 mg/dL, and BUN/SCr ratio 10.5 within 10 days (May 12, 2016) . Further improvement was observed 4 weeks after discontinuation (May 31, 2016): GFR 31.6 mL/ min/1.73 m 2 , SCr 1.7 mg/dL, BUN 10.9 mg/dL, and BUN/ SCr ratio 6.5.
Dulaglutide, furosemide, lisinopril, aspirin, and canagliflozin have the potential for AKI; however, the increase in SCr and decrease in GFR occurred after initiation of dulaglutide and resolved with discontinuation of dulaglutide only. The patient had been on other therapies months prior to initiation of dulaglutide. Per the Naranjo algorithm, this case received a score of 7: probable adverse drug reaction. 1 In clinical trials for dulaglutide, there were 2 instances of acute renal failure (one patient with concurrent sepsis and another with dehydration). 2 These findings are similar to reports of exenatide-and liraglutide-induced AKI, which most often resulted from nausea/vomiting or decreased fluid intake. [3] [4] [5] Our patient had not experienced illness and was tolerating the dulaglutide therapy well. The low BUN/SCr ratio lends itself to intrinsic renal impairment as opposed to pre-renal injury causes of impairment such as dehydration. Renal impairment was reversible, which may relate to the promptness in which injury was discovered as reports of GLP-1RA-induced (exenatide) AKI were not always reversible. 5 There were potentially precipitating factors that could have contributed to AKI in our patient including medications and conditions; however, following removal of dulaglutide therapy, the renal function improved without adjustment to any of these contributors.
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